ରେମଡେସିଭିର

ରେମଡେସିଭିର, ବ୍ରାଣ୍ଡ ନାମ ଭେକ୍ଲୁରି, ଏକ ଭୂତାଣୂରୋଧୀ ଔଷଧ ଯାହା ଅମ୍ଳଜାନ ଚିକିତ୍ସା ଆବଶ୍ୟକ କରୁଥିବା କିମ୍ବ

 

ରେମଡେସିଭିର
Clinical data
Pronunciation/rɛmˈdɛsɪvɪər/ REM-DESS-I-veer
Trade namesVeklury
SynonymsGS-5734
AHFS/Drugs.commonograph
MedlinePlusa620033
data
Pregnancy
category
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.302.974 Edit this at Wikidata
Chemical and physical data
FormulaC27H35N6O8P
Molar mass୬୦୨.୫୮ g·mol−1
3D model (JSmol)
  • CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC
  • InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
  • Key:RWWYLEGWBNMMLJ-YSOARWBDSA-N

ରେମଡେସିଭିର, ବ୍ରାଣ୍ଡ ନାମ ଭେକ୍ଲୁରି, ଏକ ଭୂତାଣୂରୋଧୀ ଔଷଧ ଯାହା ଅମ୍ଳଜାନ ଚିକିତ୍ସା ଆବଶ୍ୟକ କରୁଥିବା କିମ୍ବା ଅଧିକ ବିପଦ ପୂର୍ଣ୍ଣ କୋଭିଡ-୧୯ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।[୧୧] [୧୨] ନଭେମ୍ବର ୨୦୨୦ ମସିହାରେ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନ ଏହି ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ସର୍ତ୍ତମୂଳକ ସୁପାରିଶ କରିଥିଲା | ଏହା ଶିରାଭ୍ୟନ୍ତର ଇଞ୍ଜେକସନ ଆକାରରେ ୩ରୁ ୧୦ ଦିନ ପର୍ଯ୍ୟନ୍ତ ଦିଆଯାଏ ।[୧୩] [୧୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଧିକ ଯକୃତ ଏଞ୍ଜାଇମ ନିର୍ଗତ ହୁଏ ଏବଂ ଅଇ ଉଠିଥାଏ | [୧୩] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ହୋଇପାରେ | [୧୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ନିରାପଦ କି ନୁହେଁ ତାହା ଅସ୍ପଷ୍ଟ; ଯଦିଓ ସ୍ତନ୍ୟପାନରେ ନିରାପଦ ଅଛି | [୧୬] ଶରୀର ଭିତରେ ରେମଡେସିଭିର ରୁପାନ୍ତର ହୋଇ ଜିଏସ-୪୪୧୫୨୪ ଟ୍ରାଇଫସଫେଟରେ ପରିଣତ ହୋଇଥାଏ ଯାହା ଭୂତାଣୁ ଆରଏନଏ ପଲିମରେଜର ଏକ ରାଇବୋନିଉକ୍ଲିଓଟାଇଡ ଅନାଲଗ ଇନହିବିଟର ।[୧୭]

ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅକ୍ଟୋବର ୨୦୨୦ ମସିହାରେ ଆମେରିକାରେ ଓ ଜୁଲାଇ ୨୦୨୦ ମସିହାରେ ୟୁରୋପରେ ଅନୁମୋଦିତ ହୋଇଥିଲା [୧୨] [୧୮] ଏହା ଗିଲିଡ ବିଜ୍ଞାନ କମ୍ପାନୀଦ୍ୱାରା ବିକଶିତ ହୋଇଥିଲା ଯାହା ମୂଳତଃ ହେପାଟାଇଟିସ ସି, ଇବୋଲା ଭୂତାଣୁ ରୋଗ, ଏବଂ ମାରବର୍ଗ ଭୂତାଣୁ ରୋଗ ଚିକିତ୍ସା ନିମନ୍ତେ ଅନୁଶୀଳନ କରାଯାଇଥିଲା ।[୧୯] [୨୦] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ମସିହା ସୁଦ୍ଧା ପାଞ୍ଚ ଦିନ ପାଇଁ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୨,୬୦୦ ଡଲାର ଥିଲା | [୨୧] ବ୍ରିଟେନରେ ଏହି ରାଶି ପ୍ରାୟ ୨,୦୪୦ ପାଉଣ୍ଡ ଅଟେ | [୨୨]

 

  1. ୧.୦ ୧.୧ "Veklury Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 July 2020. Archived from the original on 13 August 2020. Retrieved 16 August 2020.
  2. "Veklury Powder for Injection Product Information". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 16 August 2020.
  3. "Veklury remdesivir 100 mg powder for injection vial". Therapeutic Goods Administration (TGA). Archived from the original on 23 October 2021. Retrieved 22 October 2021.
  4. "COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (Veklury)". Therapeutic Goods Administration (TGA). 10 July 2020. Archived from the original on 21 October 2021. Retrieved 22 October 2021.
  5. "Veklury Product information". Health Canada. 25 April 2012. Archived from the original on 26 October 2020. Retrieved 22 October 2020.
  6. ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Veklury EPAR ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  7. "Veklury 100 mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). 6 July 2020. Archived from the original on 24 November 2020. Retrieved 4 October 2020.
  8. "Veklury 100 mg powder for concentrate for solution for infusion – Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 8 October 2020. Retrieved 4 October 2020.
  9. "Remdesivir injection Remdesivir injection, powder, lyophilized, for solution". DailyMed. 1 September 2020. Archived from the original on 26 September 2020. Retrieved 25 September 2020.
  10. ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; FDA PR 20201022 ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
  11. "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
  12. ୧୨.୦ ୧୨.୧ "Veklury EPAR". European Medicines Agency (EMA). 23 June 2020. Retrieved 6 July 2020.
  13. ୧୩.୦ ୧୩.୧ "Remdesivir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
  14. "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 7 January 2022. Retrieved 7 January 2022.
  15. "Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 8 May 2020.
  16. "Remdesivir (Veklury) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Retrieved 13 July 2021.
  17. Yan, Victoria C.; Muller, Florian L. (14 May 2020). "Gilead should ditch remdesivir and focus on its simpler and safer ancestor". Stat. Boston Globe Media Partners.
  18. "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
  19. Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A (April 2020). "Current pharmacological treatments for COVID-19: What's next?". British Journal of Pharmacology. 177 (21): 4813–4824. doi:10.1111/bph.15072. eISSN 1476-5381. PMC 7264618. PMID 32329520. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  20. Stephens, Bret (18 April 2020). "The Story of Remdesivir". The New York Times. p. A23. Retrieved 11 May 2020.
  21. Chamary, J. V. "The Strange Story Of Remdesivir, A Covid Drug That Doesn't Work". Forbes (in ଇଂରାଜୀ). Retrieved 13 July 2021.
  22. "6.1. Coronavirus". British National Formulary (BNF) (82 ed.). BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 665–667. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)